Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

Mohammed Alcharakh, Seongseok Yun, Yimin Dong, Nicole D. Vincelette, Madiha Daud, Saima Manzoor, Irbaz Bin Riaz, Faiz - Anwer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

Original languageEnglish (US)
Pages (from-to)847-852
Number of pages6
JournalImmunotherapy
Volume8
Issue number8
DOIs
StatePublished - Jul 1 2016

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Stem Cells
Tissue Donors
T-Lymphocytes
Transplants
Stem Cell Transplantation
Biphenotypic Acute Leukemia
Bispecific Antibodies
Philadelphia Chromosome
Cell Lineage
B-Lymphocytes
Transplantation
blinatumomab
Lymphocytes
Cytokines
Drug Therapy
Survival
Therapeutics

Keywords

  • Biphenotypic acute leukemia
  • blinatumomab
  • CD19

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia. / Alcharakh, Mohammed; Yun, Seongseok; Dong, Yimin; Vincelette, Nicole D.; Daud, Madiha; Manzoor, Saima; Riaz, Irbaz Bin; Anwer, Faiz -.

In: Immunotherapy, Vol. 8, No. 8, 01.07.2016, p. 847-852.

Research output: Contribution to journalArticle

Alcharakh, Mohammed ; Yun, Seongseok ; Dong, Yimin ; Vincelette, Nicole D. ; Daud, Madiha ; Manzoor, Saima ; Riaz, Irbaz Bin ; Anwer, Faiz -. / Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia. In: Immunotherapy. 2016 ; Vol. 8, No. 8. pp. 847-852.
@article{82342fe25f0f451aa135624ad1f8d033,
title = "Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia",
abstract = "Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.",
keywords = "Biphenotypic acute leukemia, blinatumomab, CD19",
author = "Mohammed Alcharakh and Seongseok Yun and Yimin Dong and Vincelette, {Nicole D.} and Madiha Daud and Saima Manzoor and Riaz, {Irbaz Bin} and Anwer, {Faiz -}",
year = "2016",
month = "7",
day = "1",
doi = "10.2217/imt-2015-0023",
language = "English (US)",
volume = "8",
pages = "847--852",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

AU - Alcharakh, Mohammed

AU - Yun, Seongseok

AU - Dong, Yimin

AU - Vincelette, Nicole D.

AU - Daud, Madiha

AU - Manzoor, Saima

AU - Riaz, Irbaz Bin

AU - Anwer, Faiz -

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

AB - Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

KW - Biphenotypic acute leukemia

KW - blinatumomab

KW - CD19

UR - http://www.scopus.com/inward/record.url?scp=84978938005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978938005&partnerID=8YFLogxK

U2 - 10.2217/imt-2015-0023

DO - 10.2217/imt-2015-0023

M3 - Article

C2 - 27381683

AN - SCOPUS:84978938005

VL - 8

SP - 847

EP - 852

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 8

ER -